Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone (ITI-007) in acute schizophrenia
NCT02282761Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumateperone in schizophrenia (3 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Positive and Negative Syndrome Scale Total at 28 days. Started Nov 2014; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02282761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282761.